VERV Verve Therapeutics Inc

Price (delayed)

$7.7

Market cap

$646.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$561.01M

Highlights
Verve Therapeutics's revenue has increased by 36% from the previous quarter
VERV's gross profit is up by 36% since the previous quarter
Verve Therapeutics's equity has increased by 14% YoY but it has decreased by 2.7% from the previous quarter
The net income has declined by 10% year-on-year

Key stats

What are the main financial stats of VERV
Market
Shares outstanding
83.97M
Market cap
$646.53M
Enterprise value
$561.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
39.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.96
Earnings
Revenue
$16.05M
EBIT
-$196.45M
EBITDA
-$183.56M
Free cash flow
-$149.88M
Per share
EPS
-$2.87
Free cash flow per share
-$1.8
Book value per share
$6.97
Revenue per share
$0.19
TBVPS
$8.81
Balance sheet
Total assets
$732.36M
Total liabilities
$149.29M
Debt
$63.45M
Equity
$583.07M
Working capital
$589.03M
Liquidity
Debt to equity
0.11
Current ratio
19.82
Quick ratio
19.71
Net debt/EBITDA
0.47
Margins
EBITDA margin
-1,143.7%
Gross margin
100%
Net margin
-1,226.4%
Operating margin
-1,381.5%
Efficiency
Return on assets
-29.3%
Return on equity
-37.3%
Return on invested capital
-34.2%
Return on capital employed
-28%
Return on sales
-1,224.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VERV stock price

How has the Verve Therapeutics stock price performed over time
Intraday
7.24%
1 week
-2.04%
1 month
45.56%
1 year
-63.02%
YTD
-44.76%
QTD
57.79%

Financial performance

How have Verve Therapeutics's revenue and profit performed over time
Revenue
$16.05M
Gross profit
$16.05M
Operating income
-$221.71M
Net income
-$196.83M
Gross margin
100%
Net margin
-1,226.4%
VERV's net margin has surged by 77% year-on-year and by 28% since the previous quarter
The operating margin has soared by 76% YoY and by 27% from the previous quarter
Verve Therapeutics's revenue has increased by 36% from the previous quarter
VERV's gross profit is up by 36% since the previous quarter

Growth

What is Verve Therapeutics's growth rate over time

Valuation

What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
1.1
P/S
39.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.96
Verve Therapeutics's EPS has increased by 8% QoQ and by 8% YoY
The P/B is 46% below the last 4 quarters average of 1.9
Verve Therapeutics's equity has increased by 14% YoY but it has decreased by 2.7% from the previous quarter
The price to sales (P/S) is 68% less than the last 4 quarters average of 117.1
Verve Therapeutics's revenue has increased by 36% from the previous quarter

Efficiency

How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 77% YoY and by 28% QoQ
VERV's return on invested capital is up by 13% year-on-year and by 3.1% since the previous quarter
VERV's ROE is up by 5% QoQ
The ROA has grown by 5% YoY and by 5% from the previous quarter

Dividends

What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VERV.

Financial health

How did Verve Therapeutics financials performed over time
The quick ratio rose by 28% year-on-year and by 15% since the previous quarter
The current ratio is up by 28% year-on-year and by 15% since the previous quarter
VERV's debt is 89% smaller than its equity
VERV's debt to equity is down by 21% year-on-year
Verve Therapeutics's equity has increased by 14% YoY but it has decreased by 2.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.